News Provided By

GlobeNewswire

• Mr. Kiyoshi Kaneko appointed as Chief Commercial Officer, and Ms. Mariko Nakafuji promoted to Chief Legal Officer
  

Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed as Chief Commercial Officer (CCO), and Ms. Mariko Nakafuji is promoted into the role of Chief Legal Officer (CLO).

Mr. Kaneko brings experience in business development, corporate strategy, marketing and commercial roles within the pharmaceutical and healthcare industries in Japan. At AstraZeneca, a leading global pharmaceutical company, he held the position of Senior Vice President for its commercial organization and corporate strategy in Japan, and prior to that, as Senior Vice President of its Primary Care business unit. Since 2017, he has been Representative Director and President of Luye Life Sciences Group Japan and has led strategic partnerships with Japanese life sciences companies working across pharmaceuticals, medical devices and hospital businesses. Mr. Kaneko will take up the newly created position of CCO at Nxera and will be based in Japan.

Ms. Nakafuji joined Nxera in 2021 as General Counsel and played a key role in the Company’s transformational acquisition of the Japan and South Korean businesses of Idorsia Pharmaceuticals, as well as several other strategic projects. She previously worked at Deloitte LLP and Jones Day LLP where she specialised in corporate M&A, investments and private equity with a particular focus on the life sciences sector. Ms. Nakafuji is a qualified solicitor in England and Wales. In the new role of CLO, Ms. Nakafuji will be responsible for global (ex-Japan) legal affairs and will be based in the UK.

Leadership Team (Effective 1 April 2025)

President & Chief Executive Officer – Chris Cargill
EVP, Chief Financial Officer – Hironoshin Nomura
EVP, Chief Operating Officer – Toshihiro Maeda
EVP, President of Nxera Japan, Chief Medical Officer – Makoto Sugita
EVP, President of Nxera UK, Chief Scientific Officer – Matt Barnes
EVP, Chief Accounting Officer – Kieran Johnson
EVP, Chief Compliance Officer – Kazuhiko Yoshizumi
EVP, Chief of Staff – Candelle Chong
EVP, Chief Commercial Officer – Kiyoshi Kaneko (New)
EVP, Chief Legal Officer – Mariko Nakafuji (New)

Chris Cargill, President and CEO of Nxera, commented: “I’m delighted to welcome Mr. Kaneko to our team at Nxera. His extensive experience at global pharmaceutical companies will allow us to maximize our commercial activities in Japan and will be valuable to us as we strive to become one of the leading biopharma businesses in Japan.

“It is also a great pleasure to announce the promotion of Ms. Nakafuji to the new role of Chief Legal Officer, a very well-deserved acknowledgement of her contribution to Nxera’s transformation over the past few years and her commitment to the Company’s exciting future.”

Mr. Kiyoshi Kaneko added: “Nxera is uniquely positioning itself in the Japanese pharmaceutical industry, and I’m confident that its foresight and agility will enable the company to capitalize on the major opportunities likely to arise as the industry in Japan accelerates its development. I’m very pleased to join Nxera at such an important time of change and I look forward to being part of Nxera’s ambitious growth plans through the development of its commercialization capabilities in Japan to bring new and innovative medicines to patients.”

Ms. Mariko Nakafuji, commented: “I am proud to step into the new role of Chief Legal Officer and look forward to working closely with the talented team to further advance our mission and build Nxera into a leading biopharma company in Japan and internationally.”

–END–

About Nxera Pharma
Nxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates.

Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera – Media and Investor Relations
Kentaro Tahara, VP Investor Relations and Corporate Strategy
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: www.einpresswire.com

Apple is developing a new version of its Health app that includes an AI coach that can advise users on how to get healthier, according to Bloomberg’s Mark Gurman.

Gurman first reported that something like this was in the works back in 2023, but now he says development is moving ahead, with the new features potentially coming as soon as spring or summer of 2026, with the release of iOS 19.4.

The AI coach’s advice would be based on data from across users’ medical devices, and would reportedly include food tracking. The coach is currently being trained on data from staff physicians, with Apple looking to bring in additional doctors to record health-related videos.

According to Gurman, this new service is tentatively called Health+.

Topics

Source:https://techcrunch.com/

In UNESCO’s International Year of Quantum Science and Technology, Europe’s largest quantum event convenes enterprise, academia, and quantum pioneers in London.

LONDON, UNITED KINGDOM, April 1, 2025 /EINPresswire.com/ — Economist Impact will hold its fourth annual Commercialising Quantum Global Summit May 13th-14th 2025, bringing together enterprise end users, world-renowned academics, and quantum technology pioneers. Taking place at The Business Design Centre, the agenda navigates critical discussions including the intersection of quantum and AI, when we might achieve quantum advantage, and the real-world applications of quantum, from climate to cybersecurity.

This year’s summit comes at a pivotal and exciting moment for the quantum industry. According to research published last month from Oxford Economics, IBM, and Oxford Quantum Circuits, quantum computing could deliver up to £212 billion of gross value to UK GDP alone by 2045. Globally, quantum is on track to create up to $850 billion of economic value by 2040, demonstrating the scale of the opportunity.

Already this year, there have been significant shake-ups and sizable announcements from some of the biggest players in the industry. In January, NVIDIA CEO Jensen Huang sent ripples through international news and the stock market after declaring that quantum utility was another thirty years away, only to go back on his timeline at the company’s GTC Conference in March. Microsoft meanwhile launched its quantum chip, the Majorana 1, predicting that it will solve industrial scale problems in years, not decades. Amazon also joined the emerging race between tech giants by unveiling its quantum chip, Ocelot.

During this growing global attention and rapid technological progress, distinguishing hype from reality has never been more important.

At Commercialising Quantum, a case-study led agenda will cover the full spectrum of quantum technologies and explore their applications and impact. Some of the key themes include how we transition quantum computing from the theoretical to the practical and useful, how quantum technologies like sensing have the potential to accelerate progress towards the UN Sustainable Development Goals, and how businesses can secure critical data in the midst of changing quantum-safe encryption standards. With 2025 marking the UNESCO’s International Year of Quantum Science and Technology, the event is set to drive further engagement and awareness of quantum technologies in a landmark year.

Guided by The Economist’s editors, participants will join more than 1,000 global leaders, policy makers and business executives from over 40 countries for an accessible debate into the promise, peril, applications, limitations, hype, and reality of this field.

The two-day programme will host a lineup of over one hundred speakers from government, industry and academia, including Lord Patrick Vallance, Minister of state for science, research and innovation, Matija Matokovic, Deputy head of innovation, NATO, and Dr Peter Thompson, Chief executive, National Physical Laboratory. Sponsors include IBM Quantum, Microsoft, Deloitte, Q-CTRL, PQShield, and Rigetti.

Speaking about the upcoming event, Helen Ponsford, Head of trade, technology, industry events programming at Economist Impact, comments:

“We have seen quantum make headlines this year, from predictions of quantum advantage to breakthroughs in innovation. The industry has made huge strides towards commercialisation over the past 12 months, but there is still much to discover. Coinciding with UNESCO’s International Year of Quantum, there is no better time to convene industry leaders, media representatives, academia, and end-users to explore industry progress and the path towards implementing this transformative technology. We are thrilled to bring our Commercialising Quantum Global to London for the fourth year running, and look forward to a jam-packed programme of discussion, insights, and innovation.”

Key information:

When: May 13th – 14th, 2025
Where: Business Design Centre, 52 Upper St, London N1 0QH, in-person

For registration and further details:

Press Registration
General Registration

— ends —

About Economist Impact
Economist Impact combines the rigour of a think-tank with the creativity of a media brand to engage a globally influential audience. We believe that evidence-based insights can open debate, broaden perspectives and catalyse progress. The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events, El Studios and SignalNoise.

Our track record spans 75 years across 205 countries. Along with creative storytelling, events expertise, design-thinking solutions and market-leading media products, we produce framework design, benchmarking, economic and social impact analysis, forecasting and scenario modelling, making Economist Impact’s offering unique in the marketplace. Visit www.economistimpact.com for more information.

About The Economist (www.economist.com)
With a growing global circulation and a reputation for insightful analysis and perspective on every aspect of world events, The Economist is one of the most widely recognised and well-read current affairs publications. The paper covers politics, business, science and technology, and books and arts, concluding each week with the obituary. In addition to the web-only content such as blogs, debates and audio/video programmes available on the website, The Economist is available to download for reading on Android, Blackberry PlayBook, iPhone or iPad devices. The Economist Espresso, our daily briefing smartphone app, is also available for download via iTunes App Store or Google Play.

For information on sponsorship, speaking slots, or attendance, contact:
Helen Ponsford
Senior Programme Editor, Economist Impact
helenponsford@economist.com

For media enquiries, contact:

Naomi Stewart
Economist Impact
naomistewart@economist.com

Source: https://www.einpresswire.com